A considerable part of the global activities for the development and production of diagnostics, vaccines and drugs against Covid-19 takes place at biotech sites in German-speaking countries. Companies such as BioNTech, CureVac or QIAGEN have gained global recognition in the public eye virtually overnight. But these flagships are only the tip of the iceberg of innovative biotechnology companies in Germany.
The e-Vent will…
- Give the opportunity to discuss funding, procurement and governmental support
- Give the opportunity to exchange an discuss experiences made with corona research
- Provide industry insights and expert views for press representatives and government employees
17 presentations by companies that are researching vaccines or therapies or have diagnostics or other services on the market will be the core of the three-day programme. On April 28, we will present the brand-new figures of the German biotechnology industry. In addition, there will be keynotes and panel discussions on all three days.
Attending the live program is already possible from 50 €. Register now: https://corona.ascrion.com